HHMI to Boost, Broaden Spending on Research

WASHINGTON—The Howard Hughes Medical Institute has promised to increase its spending by $500 million during the next decade as part of an agreement this month that ends its longstanding dispute with the Internal Revenue Service. Researchers, science students, and teachers at U.S. schools and universities may eventually be among the beneficiaries of the settlement, which requires HHMI to spend an additional $50 million a year above the $200 million it now devotes to medical research. The ag

Written byStephen Greene
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Researchers, science students, and teachers at U.S. schools and universities may eventually be among the beneficiaries of the settlement, which requires HHMI to spend an additional $50 million a year above the $200 million it now devotes to medical research. The agreement also relaxes some restrictions on the nonprofit institute, permitting it for the first time to finance educational grants and fellowships for independent researchers.

"It's an outstanding opportunity for us," said George Thorn, president of HHMI's board of trustees. "The $500 million can all be spent toward areas we're interested in funding. It's a push in the right direction in two ways: more money is available and we now have more flexibility in spending it."

HHMI President Donald T. Fredrickson said the institute, which is based in Bethesda, Md., will continue to devote 75 to 80 percent of its annual expenditures to research in genetics, immunology, cell biology and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies